Sahm Nasseri joined Biotheryx as Chief Business Officer in January 2022. Sahm is responsible for the Company’s business development, corporate strategy, corporate development and program management functions. He previously served as Chief Executive Officer of PYC Therapeutics, where he was instrumental in building out the Company’s U.S. presence and preclinical, clinical and corporate development teams. Prior, Sahm worked at Merck & Co. for seven years as a leader across business development, investor relations and corporate strategy functions involving extensive commercial drug development experience. During this time, he led global strategy for Merck’s growing oncology organization and served as interim Vice President and Global Product Leader for Merck’s HPV Vaccines. Before Merck, Sahm was a Strategy Consultant with McKinsey & Company in Australia. Sahm holds a B.S. in chemical engineering from the University of New South Wales in Sydney and an M.B.A. from Columbia Business School in New York City.